MEDI 545

BIOLOGICAL3 trials

Sponsors

MedImmune LLC

Conditions

Chronic Plaque PsoriasisLupus

Phase 1

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

CompletedNCT00299819

MedImmune LLCLupus

Start: 2006-03-31End: 2007-10-31Updated: 2007-12-18

A Multicenter Study to Evaluate the Safety and Tolerability of Single-Dose for MEDI-545

CompletedNCT00472758

MedImmune LLCChronic Plaque Psoriasis

Start: 2007-02-28End: 2008-03-31Updated: 2011-11-17

A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus

CompletedNCT00482989

MedImmune LLCLupus

Start: 2007-06-30End: 2010-09-30Updated: 2012-07-11

Related Papers

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.

2011-07-27183 citations